Stephen B. Baylin

This paper shows that STING agonists combined with epigenetic drugs enhance necroptosis in TP53-mutated AML by activating STING and upregulating interferon-related genes.

The paper analyzes bone marrow microenvironment changes in HMA-resistant MDS patients treated with guadecitabine and atezolizumab, finding that long-term survivors show reduced immunosuppressive monocytes and expanded effector lymphocytes.

This paper identifies EZH1-dependent H3K27me1 as an adaptive chromatin barrier limiting DNMT inhibitor response in colorectal cancer and shows that dual EZH1/2 inhibition synergizes with DNMTi to enhance therapeutic efficacy.

This study identifies that combining MYC inhibition with class IIa HDAC inhibition enhances mitochondrial dysfunction and reduces viability in NSCLC cell lines.

This study identifies ZNFX1 as a master regulator of epigenetically-induced pathogen mimicry and inflammasome signaling in ovarian cancer, linking its expression to disease progression and survival.

This study shows UHRF1 ubiquitin ligase activity and DNMT1 ubiquitin reading activity are essential for maintaining low-density CpG methylation, and their disruption leads to hypomethylation and PMD formation in cancer.

The paper identifies a lncRNA signature associated with SARS-CoV-2 infection through transcriptomic analysis and functional correlation studies.

This study investigates how SARS-CoV-2 infection affects mitochondrial gene expression in different tissues and disease stages, finding targeted inhibition in some organs and upregulation in others.

The paper investigates differential alternative splicing in cells infected by betacoronaviruses and finds characteristic patterns linked to viral load and gene function.

The paper identifies miR-2392 as a miRNA involved in SARS-CoV-2 infection, showing its role in inflammation, glycolysis, and hypoxia, and develops a miRNA-based therapeutic targeting it.

This study identifies germline genetic variants influencing somatic mutation patterns in 2,642 cancer genomes across 39 cancer types.

This study characterizes mitochondrial genomes in 2,700 cancer patients across 37 types using whole-genome sequencing and RNA-seq, revealing mutational patterns, truncating mutations, and nuclear transfer of mitochondrial DNA.